Inventor · disambiguated record
Alejandro V. Villagra
Also filed as: VILLAGRA ALEJANDRO · VILLAGRA ALEJANDRO V
11 granted patents·7 pending applications·45 citations·filing 2013–2024
87Inventor score
Files withH LEE MOFFITT CANCER CT & RES11THE GEORGE WASHINGTON UNIV A CONGRESSIONALLY CHARTERED NOT FOR PROFIT CORPORATION4UNIV GEORGE WASHINGTON2UNIV ILLINOIS1
Top patents by PatentIndex Score
18 records- 0194US10016421B2Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccinationH LEE MOFFITT CANCER CT & RES·Filed 2015·Granted Jul 10, 2018·10 cites·14 claims
- 0294US9987258B2Histone deacetylase as a modulator of PDL1 expression and activityH LEE MOFFITT CANCER CT & RES·Filed 2015·Granted Jun 5, 2018·10 cites·5 claims
- 0394US9409858B2Selective histone deactylase 6 inhibitorsH LEE MOFFITT CANCER CT & RES·Filed 2013·Granted Aug 9, 2016·11 cites·22 claims
- 0492US9751832B2Selective histone deactylase 6 inhibitorsH LEE MOFFITT CANCER CT & RES·Filed 2014·Granted Sep 5, 2017·11 cites·7 claims
- 0588US12024493B2Isoxazole hydroxamic acids as histone deacetylase 6 inhibitorsTHE GEORGE WASHINGTON UNIV A CONGRESSIONALLY CHARTERED NOT FOR PROFIT CORPORATION·Filed 2022·Granted Jul 2, 2024·1 cites·15 claims
- 0682US10918638B2Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccinationH LEE MOFFITT CANCER CT & RES·Filed 2018·Granted Feb 16, 2021·1 cites·10 claims
- 0777US11472780B2Isoxazole hydroxamic acids as histone deacetylase 6 inhibitorsTHE GEORGE WASHINGTON UNIV A CONGRESSIONALLY CHARTERED NOT FOR PROFIT CORPORATION·Filed 2018·Granted Oct 18, 2022·1 cites·8 claims
- 0874US2022184047A1Histone deacetylase as a modulator of pdli expression and activityH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 0970US10576066B2Histone deacetylase as a modulator of PDLI expression and activityH LEE MOFFITT CANCER CT & RES·Filed 2018·Granted Mar 3, 2020·0 cites·4 claims
- 1066US2022000867A1Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccinationH LEE MOFFITT CANCER CT & RES·Filed 2021·Application pending·0 cites
- 1165US2020188366A1Histone deacetylase as a modulator of pdli expression and activityH LEE MOFFITT CANCER CT & RES·Filed 2020·Application pending·0 cites
- 1263US2024366661A1Compositions for and methods of treating a subject having inflammationUNIV GEORGE WASHINGTON·Filed 2024·Application pending·0 cites
- 1361US2023391868A1Compositions for and methods of treating cancerUNIV GEORGE WASHINGTON·Filed 2023·Application pending·0 cites
- 1459US10227295B2Selective histone deactylase 6 inhibitorsH LEE MOFFITT CANCER CT & RES·Filed 2017·Granted Mar 12, 2019·0 cites·15 claims
- 1559US9956192B2Selective histone deactylase 6 inhibitorsH LEE MOFFITT CANCER CT & RES·Filed 2016·Granted May 1, 2018·0 cites·25 claims
- 1655US2023250054A1Selective histone deacetylase 6 inhibitorsUNIV ILLINOIS·Filed 2021·Application pending·0 cites
- 1747US2023405118A1Stat-activated macrophages, compositions, and uses thereofTHE GEORGE WASHINGTON UNIV A CONGRESSIONALLY CHARTERED NOT FOR PROFIT CORPORATION·Filed 2021·Application pending·0 cites
- 1846US12485174B2HDAC6-activated macrophages, compositions, and uses thereofTHE GEORGE WASHINGTON UNIV A CONGRESSIONALLY CHARTERED NOT FOR PROFIT CORPORATION·Filed 2020·Granted Dec 2, 2025·0 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when Alejandro V. Villagra files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →